ASCO GI 2019: Post-Conference News on CRC - Episode 6

Real-World Management of Patients with BRAF-V600E mCRC

Scott Kopetz, MD, PhD, FACP, provides advice on the management of patients with BRAFV600E-mutant metastatic colorectal cancer with the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen studied in the BEACON and ANCHOR trials.